Background

Pathogenic viruses such as Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Herpes Simplex Virus penetrate host cells and hide their genetic material by integrating into the host genome or existing as circular episomes. While antiviral drugs can suppress viral replication in the blood, they cannot eliminate the latent reservoirs hidden within chromatin. This is why viruses reactivate and resume replication the moment a patient stops medication.

Molecular biology researchers have previously attempted to use CRISPR-Cas9 gene scissors to cleave the viral DNA itself inserted into the host chromosomes. However, methods inducing DNA Double-Strand Breaks (DSB) within the human genome inevitably carry the risk of off-target cleavage. It is difficult to rule out the possibility of fatal genomic instability, such as chromosomal translocation, large-scale deletions, or the activation of oncogenic genes. In particular, damage to human-specific sequences similar to viral sequences causes severe cytotoxicity, hindering clinical progression. Consequently, there was an urgent need for a new molecular biological control technology that could selectively block latent viral gene expression without directly damaging the gene sequence.

Key Findings

Instead of cutting the DNA sequence itself, researchers established an epigenetic editing platform that chemically modifies the chromatin structure. They designed a complex fusing catalytically dead Cas9 (dCas9)—which lacks cleavage activity—with a DNA Methyltransferase (DNMT) catalytic domain and the KRAB (Kruppel-associated box) repressive transcriptional factor domain. The guide RNA (gRNA) was engineered to precisely recognize the Long Terminal Repeat (LTR) sequence, a key transcriptional initiation region of the viral promoter.

When applied to an in vitro human T-cell latent infection model, the complex demonstrated remarkable inhibitory effects. The methylation rate of the fifth carbon of cytosine in CpG islands within the target LTR region increased by more than 82% compared to the baseline. Simultaneously, the enrichment of the repressive histone marker H3K9me3 (histone H3 lysine 9 trimethylation) rose more than fourfold, rapidly inducing heterochromatinization where the chromatin condenses tightly.

In latent reversal tests, where viral reactivation is induced using strong chemical stimulants, the production of viral RNA transcripts remained suppressed by over 98%. This was achieved by blocking the access pathway so that transcriptional activation factors could not physically bind to the promoter. Even more notable was the persistence. Even after tracking the cultured cells through more than 60 divisions, the methylation marks were stably replicated during cell division, maintaining the state of viral expression silencing. Analysis via RNA-seq and Whole-Genome Bisulfite Sequencing (WGBS) showed that non-target expression disturbances in human host genes or chromosomal structural abnormalities were below the detection limit.

Significance and Outlook

This achievement demonstrates a paradigm shift in functionally neutralizing viruses without genome cleavage. It demonstrates that even without completely eliminating latent reservoir viruses, a functional cure in the absence of antivirals can be approached by locking genetic traces in an inactive state. Expansion of indications is expected for various refractory viral diseases, not only HIV but also those that persist in latent form in ganglia after infection, such as herpes simplex virus, and chronic hepatitis B, which persists in the form of cccDNA within hepatocyte nuclei.

The tasks are also clear. Optimizing in vivo delivery vehicles capable of delivering the editing complex to deep tissues and latent immune cells is essential. During the process of delivery to target tissues via Lipid Nanoparticles (LNP) or Adeno-Associated Virus (AAV) vectors, the immune response must be minimized. Follow-up studies are needed to verify in non-human primate models whether the epigenetic silencing state persists for several years over the long term.